Complicated Intra-Abdominal Infections ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Complicated Intra-Abdominal Infections ' Pipeline Review, H2 2012
Published on September 2012

Report Summary


Summary

Global Markets Direct's, 'Complicated Intra-Abdominal Infections - Pipeline Review, H2 2012', provides an overview of the indication's
therapeutic pipeline. This report provides information on the therapeutic development for Complicated Intra-Abdominal Infections,
complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the
therapeutic development for Complicated Intra-Abdominal Infections. Complicated Intra-Abdominal Infections - Pipeline Review, Half
Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites,
SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Complicated Intra-Abdominal Infections.
- A review of the Complicated Intra-Abdominal Infections products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Complicated Intra-Abdominal Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Complicated Intra-Abdominal Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Complicated Intra-Abdominal Infections pipeline depth and focus
of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Complicated Intra-Abdominal Infections ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Complicated Intra-Abdominal Infections Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Complicated Intra-Abdominal Infections 7
Complicated Intra-Abdominal Infections Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Early Clinical Stage Products 12
Pre-Clinical Stage Products 13
Complicated Intra-Abdominal Infections Therapeutics ' Products under Development by Companies 14
Companies Involved in Complicated Intra-Abdominal Infections Therapeutics Development 15
AstraZeneca PLC 15
Rib-X Pharmaceuticals, Inc. 16
Cubist Pharmaceuticals, Inc. 17
Paratek Pharmaceuticals, Inc. 18
Atox Bio Inc. 19
Tetraphase Pharmaceuticals Inc. 20
Complicated Intra-Abdominal Infections ' Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
omadacycline - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
delafloxacin - Drug Profile 29
R&D Progress 29
CXA201 - Drug Profile 32
R&D Progress 32



AB-103 - Drug Profile 34
R&D Progress 34
TP-434 - Drug Profile 35
R&D Progress 35
CAZ104 - Drug Profile 36
R&D Progress 36
CXA-201 + Metronidazole - Drug Profile 38
R&D Progress 38
CAZ104 + Metronidazole - Drug Profile 40
R&D Progress 40
Complicated Intra-Abdominal Infections Therapeutics ' Drug Profile Updates 42
Complicated Intra-Abdominal Infections Therapeutics - Dormant Products 48
Complicated Intra-Abdominal Infections ' Product Development Milestones 49
Featured News & Press Releases 49
Sep 05, 2012: Tetraphase Pharma To Present New Clinical And Preclinical Research On Antibiotic Portfolio At ICAAC 2012 49
Dec 13, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Intra-Abdominal
Infections 49
Jun 16, 2005: FDA Approves Tygacil, First-in-class Antibiotic 50
May 26, 2005: The US FDA Approves New Indication For Merrem I.V for Complicated Skin and Skin Structure Infections 50
Jan 28, 2005: FDA Grants Tygacil (Tigecycline) NDA Priority Review Status 51
Aug 02, 2004: AstraZeneca Submits supplemental New Drug Application to the U.S. Food and Drug Administration for Merrem I.V for
a new indication of skin and skin structure infections 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables

Number of Products Under Development for Complicated Intra-Abdominal Infections, H2 2012 7
Products under Development for Complicated Intra-Abdominal Infections ' Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11



Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
AstraZeneca PLC, H2 2012 15
Rib-X Pharmaceuticals, Inc., H2 2012 16
Cubist Pharmaceuticals, Inc., H2 2012 17
Paratek Pharmaceuticals, Inc., H2 2012 18
Atox Bio Inc., H2 2012 19
Tetraphase Pharmaceuticals Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Complicated Intra-Abdominal Infections Therapeutics ' Drug Profile Updates 42
Complicated Intra-Abdominal Infections Therapeutics ' Dormant Products 48

List of Figures

Number of Products under Development for Complicated Intra-Abdominal Infections, H2 2012 7
Products under Development for Complicated Intra-Abdominal Infections ' Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Complicated Intra-Abdominal Infections ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Complicated Intra-Abdominal Infections ' Pipeline Review, H2 2012